×

Profound Medical Corp. Announces World’s First Sale of TULSA-PRO for Prostate Ablation

TORONTO, April 28, 2016 (GLOBE NEWSWIRE) -- Profound Medical Corp. (“Profound” or “Company”) (TSXV:PRN), a medical device company commercializing a unique, Magnetic Resonance (“MR”) guided ablation procedure for prostate care, today announced the first sale of its TULSA-PRO device to ResoFus Alomar in Barcelona, Spain.

Mr. Antonio Alomar Serrallach, CEO and founder of ResoFus Alomar, is delighted to be the world’s first commercial customer to purchase this technology and offer precise ablation of targeted prostate tissue to their patients. Mr. Serrallach is a well-respected pioneer, best known for his adoption of innovative technology approaches in MR guided ultrasound ablation. As a result of ResoFus Alomar’s acquisition of a Siemens Skyra system, the Centre has the capacity to start performing the TULSA procedure in the very near future.

“On the heels of our recent CE Marking, we are delighted to announce our first commercial sale of a TULSA system to the notable ResoFus Alomar,” said Steve Plymale, CEO, Profound Medical Corp. “We look forward to the day when the Centre’s clinicians treat their first patient with this procedure. As an alternative to surgery or radiation, we are confident that our minimally invasive therapy will provide great benefit to the clinicians and patients at this facility.”

Profound’s novel technology combines real-time Magnetic Resonance (MR) imaging with transurethral robotically-driven ultrasound and closed-loop thermal feedback control, providing a highly precise treatment tailored to patient-specific anatomy and pathology.TULSA-PRO has demonstrated accurate and precise ablation of prostate tissue, both malignant and benign, while providing a favourable safety profile and a low side effect profile.

About Profound Medical Corp.

Profound Medical is a Canadian medical device company that has developed a unique MR guided ablation procedure for prostate care. Profound’s novel technology combines real-time MR imaging with transurethral, robotically-driven therapeutic ultrasound and closed-loop thermal feedback control. It provides a highly precise treatment tailored to patient-specific anatomy and pathology. This method of prostate ablation offers short treatment times and low morbidity, allowing for fast patient recovery. For more information, visit profoundmedical.com

Notice regarding forward-looking statements:

This release includes forward-looking statements regarding Profound and its business which may include, but is not limited to, the expectations regarding the efficacy of Profound’s technology in the treatment of prostate cancer. Often, but not always, forward-looking statements can be identified by the use of words such as "plans", "is expected", "expects", "scheduled", "intends", "contemplates", "anticipates", "believes", "proposes" or variations (including negative variations) of such words and phrases, or state that certain actions, events or results "may", "could", "would", "might" or "will" be taken, occur or be achieved. Such statements are based on the current expectations of the management of Profound. The forward-looking events and circumstances discussed in this release, may not occur by certain specified dates or at all and could differ materially as a result of known and unknown risk factors and uncertainties affecting the company, including risks regarding the pharmaceutical industry, economic factors, the equity markets generally and risks associated with growth and competition. Although Profound has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other factors that cause actions, events or results to differ from those anticipated, estimated or intended. No forward-looking statement can be guaranteed. Except as required by applicable securities laws, forward-looking statements speak only as of the date on which they are made and Profound undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise, other than as required by law.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

For investor or media inquiries, please contact: Steve Plymale CEO Profound Medical Corp. splymale@profoundmedical.com T: 647-476-1350, Ext. 401 Or Rebecca von Goetz Senior Marketing & Communications Specialist Profound Medical Corp. rvongoetz@profoundmedical.com T: 647-476-1350, Ext. 426 C: 416.917.8650

Source:Profound Medical Inc.